Loading...
Please wait, while we are loading the content...
Similar Documents
Risk of second cancers in Waldenström macroglobulinemia.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Varettoni, Marzia Tedeschi, Alessandra Arcaini, Luca Pascutto, Cristiana Vismara, Eleonora Orlandi, Ester Maria Ricci, Francesco Corso, Alessandro Greco, Andrea Mangiacavalli, Silvia Lazzarino, Mario Morra, E. Lalia |
| Copyright Year | 2012 |
| Abstract | BACKGROUND An increased incidence of second cancers has been reported in lymphoproliferative disorders. PATIENTS AND METHODS We assessed the frequency, characteristics and predictive factors of second cancers in 230 patients with Waldenström macroglobulinemia (WM) and compared the incidence of second cancers in WM with that of an age- and sex-matched control population. RESULTS Twenty-two patients (10%) developed solid cancers and 10 (4%) second hematologic malignancies. In a competing risk model, the cumulative incidence of solid cancers was 12% at 10 years and 17% at 15 years while the incidence of hematologic malignancies was 6% and 8%, respectively. The overall risk of second cancer in WM was 1.69 times higher than expected (P = 0.002). WM patients were at increased risk for diffuse large B-cell lymphoma [standardized incidence ratio (SIR) 9.24, P < 0.0001], myelodisplastic syndrome/acute myeloid leukemia (SIR 8.4, P < 0.0001), brain cancer (SIR 8.05, P = 0.0004). The risk of a second hematologic malignancy was fourfold higher in patients previously treated, though not reaching statistical significance (P = 0.19). CONCLUSIONS WM patients are at higher risk of second cancers as compared with the general population. The sample size does not allow firm conclusions about the effect of therapy on the development of second cancers. |
| Starting Page | 978 |
| Ending Page | 991 |
| Page Count | 14 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/annonc/23/2/10.1093/annonc/mdr119/2/mdr119.pdf?Expires=1492584852&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q&Signature=P10quWwfwIMLKxcITqB4D7OWJhRmdZZtS-c0FOd~LnH07EpdWvxwsKAL6R~FJYDjr4V0~5sYQghqNXNGFbwW09ftyE8LYo64NAhCy858WCHlZLj3i~PaeQvNyUPQwZvZDczJ-j9mAwUl6dAPm5SNRvXHa0EU8857ukUARufVzsaxqyNNY41aALBrnAK0N6bL6lBVQoaXnxXdbBzjhQbkMeXGVMvOvmf-HHTMjCq7wW~cmiwf8K5lbp0eskX1SWqgrCyAEGqzMcpJlTKEHpK-hxK3b8SXyYS3FyTe4Amkwf6BCu7~QeabMttyCOen-tpq6j5pInyJ~cJDixR8eL553Q__ |
| PubMed reference number | 21525403v1 |
| Alternate Webpage(s) | https://doi.org/10.1093/annonc/mdr119 |
| DOI | 10.1093/annonc/mdr119 |
| Journal | Annals of oncology : official journal of the European Society for Medical Oncology |
| Volume Number | 23 |
| Issue Number | 2 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | B-Cell Lymphomas Cellular Phone Diffuse Large B-Cell Lymphoma Hematologic Neoplasms Hematology (discipline) Leukemia, B-Cell Leukemia, Myelocytic, Acute Lymphoproliferative Disorders Malignant Neoplasms Malignant neoplasm of brain Myeloid Leukemia P-Value Patients Second Primary Cancers Waldenstrom Macroglobulinemia |
| Content Type | Text |
| Resource Type | Article |
